Neoplastic human embryonic stem cells as a model of radiation resistance of human cancer stem cells

Oncotarget

Volumn 6, Issue 26, 2015, Pages 22258-22269

  Dingwall, Steve ^a,b   Lee, Jung Bok ^a   Guezguez, Borhane ^a   Fiebig, Aline ^a   McNicol, Jamie ^a   Boreham, Douglas ^b   Collins, Tony J ^a   Bhatia, Mick ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Cancer stem cells; Human stem cells; Radiation resistance

Indexed keywords

PROTEIN BCL XL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STEM CELL; CELL CYCLE ARREST; CELL DEATH; CELL POPULATION; CONTROLLED STUDY; EMBRYONAL CARCINOMA STEM CELL; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIOSENSITIVITY; TERATOCARCINOMA; TRANSFORMED HUMAN EMBRYONIC STEM CELL; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN EMBRYONIC STEM CELL; NEOPLASMS; NONOBESE DIABETIC MOUSE; PATHOLOGY; RADIATION RESPONSE; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; HETEROGRAFTS; HUMAN EMBRYONIC STEM CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84941194629     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4165     Document Type: Article

References (38)

1. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005; 104:1129-1137.
2. Dawson LA, Sharpe MB. Image-guided radiotherapy: rationale, benefits, and limitations. The lancet oncology. 2006; 7:848-858.
3. Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. The lancet oncology. 2008; 9:367-375.
4. Zielske SP, Spalding AC, Wicha MS, Lawrence TS. Ablation of breast cancer stem cells with radiation. Transl Oncol. 2011; 4:227-233.
5. Desgrandchamps F. Recurrence following radiotherapy. Front Radiat Ther Oncol. 2008; 41:86-92.
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444:756-760.
7. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. Journal of the National Cancer Institute. 2006; 98:1777-1785.
8. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133-cells, and the CD133+ sector is enlarged by hypoxia. International journal of radiation oncology, biology, physics. 2007; 67:1-5.
9. Chiou SH, Kao CL, Chen YW, Chien CS, Hung SC, Lo JF, Chen YJ, Ku HH, Hsu MT, Wong TT. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PloS one. 2008; 3:e2090.
10. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009; 69:1302-1313.
11. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009; 458:780-783.
12. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci U S A. 2010; 107:3522-3527.
13. Werbowetski-Ogilvie TE, Bosse M, Stewart M, Schnerch A, Ramos-Mejia V, Rouleau A, Wynder T, Smith MJ, Dingwall S, Carter T, Williams C, Harris C, Dolling J, Wynder C, Boreham D, Bhatia M. Characterization of human embryonic stem cells with features of neoplastic progression. Nature biotechnology. 2009; 27:91-97.
14. Werbowetski-Ogilvie TE, Morrison LC, Fiebig-Comyn A, Bhatia M. In vivo generation of neural tumors from neoplastic pluripotent stem cells models early human pediatric brain tumor formation. Stem Cells. 2012; 30:392-404.
15. Blagosklonny MV. Cancer stem cell and cancer stemloids: From biology to therapy. Cancer Biology & Therapy. 2007; 6:1684-1690.
16. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, Levadoux-Martin M, Lee JB, Giacomelli AO, Hassell JA, Fischer-Russell D, Trus MR, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012; 149:1284-1297.
17. Damjanov I, Andrews PW. The terminology of teratocarcinomas and teratomas. Nat Biotech. 2007; 25:1212-1212.
18. Fulop GM, Phillips RA. The scid mutation in mice causes a general defect in DNA repair. Nature. 1990; 347:479-482.
19. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wohrer S, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012; 12:767-775.
20. Fournier C, Taucher-Scholz G. Radiation induced cell cycle arrest: an overview of specific effects following high-LET exposure. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2004; 73:S119-122.
21. Momcilovic O, Choi S, Varum S, Bakkenist C, Schatten G, Navara C. Ionizing radiation induces ataxia telangiectasia mutated-dependent checkpoint signaling and G(2) but not G(1) cell cycle arrest in pluripotent human embryonic stem cells. Stem Cells. 2009; 27:1822-1835.
22. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137:413-431.
23. Campbell CJ, Lee JB, Levadoux-Martin M, Wynder T, Xenocostas A, Leber B, Bhatia M. The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood. 2010; 116:1433-1442.
24. Colak S, Zimberlin CD, Fessler E, Hogdal L, Prasetyanti PR, Grandela CM, Letai A, Medema JP. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 2014; 21:1170-1177.
25. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi Y-X, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10:375-388.
26. Bijnsdorp I, Giovannetti E, Peters G. 2011; Analysis of Drug Interactions. in: Cree IA, ed, Cancer Cell Culture. Humana Press: 2011;:421-434.
27. Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer. Lucy Wortham James clinical research award. Arch Surg. 1987; 122:1244-1247.
28. Lindberg RD, Fletcher GH. The role of irradiation in the management of head and neck cancer: analysis of results and causes of failure. Tumori. 1978; 64:313-325.
29. Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, Hilaris BS, Whitmore WF. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. International journal of radiation oncology, biology, physics. 1991; 21:537-547.
30. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007; 67:8980-8984.
31. Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells. 2010; 28:639-648.
32. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ, Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992; 71:587-597.
33. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009; 458:780-783.
34. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 2006; 13:1351-1359.
35. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2009; 1787:414-420.
36. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nature genetics. 2006; 38:500-501.
37. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:15545-15550.
38. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature genetics. 2003; 34:267-273.